The Brand Name LITHICAB Has Generic Salt :: Lithium 

LITHICAB  Is From Company TASMED Priced :: Rs. 8.9

LITHICAB have Lithium is comes under Sub class #N/A of  Main Class #N/A

Main Medicine Class:: #N/A  Sub Medicine Class :: #N/A 

Indications for Drugs ::

Bipolar disorder, Mania, Recurrent unipolar depression

Drug Dose ::

Oral: Adult: Extended release: 900-1800 mg/day PO divided 12 hourly Lower initial dosage may be used to minimize adverse drug reactions Serum lithium should be monitored 12 hours after dose, twice weekly until serum concentration and clinical condition stabilize, and every other month thereafter Desirable range for serum lithium: 0.6-1.2 mEq/L; although higher serum concentrations may be needed, not to exceed 1.5 mEq/L

Contraindication ::

Renal insufficiency, cardiovascular insufficiency, Addison’s disease and untreated hypothyroidism are all contraindications to lithium therapy.

Drug Precautions ::

Decreased tolerance to lithium has been reported to ensue from protracted sweating or diarrhoea and, if such occur, supplemental fluid and salt should be administered under careful medical supervision and lithium intake reduced or suspended until the condition is resolved.

Drug Side Effects ::

Tiredness, loss of appetite, nausea, vomiting, diarrhoea, hands shaking, memory problems, increased thirst and consequently passing urine more often by day, and perhaps also by night.

Pregnancy category ::

4

Drug Mode of Action ::  

Inhibits postsynaptic D2 receptor supersensitivity. Alters cation transport in nerve and muscle cells and influences reuptake of serotonin or norepinephrine. Inhibits phosphatidylinositol cycle second messenger systems.

Drug Interactions ::

Reduced serum levels with carbonic anhydrase inhibitors, chlorpromazine, sodium-containing preparations, theophylline, urea. Enhanced hypothyroid effects with iodine salts. Enhanced effects of neuromuscular-blocking agents. Reduced pressor response to sympathomimetics. Potentially Fatal: Increased risk of lithium toxicity with ACE inhibitors, angiotensin receptor antagonists, loop diuretics, metronidazole, phenytoin. Increased risk of neurotoxicity with carbamazepine, calcium-channel blockers, haloperidol, methyldopa, phenothiazines, SSRIs, TCAs. Increased serum levels with COX-2 inhibitors, NSAIDs (except sulindac, aspirin), tetracyclines, thiazide diuretics. Increased risk of encephalopathy with haloperidol. Increased risk of serotonin syndrome with sibutramine. Fatal malignant hyperpyrexia may occur when used with MAOIs.